3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Filgrastim
7
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Etoposide
4
Carboplatin
4
Busulfan
4
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
tanespimycin
2
Thiotepa
2
Temozolomide
2
Mesna
2
Docetaxel
2
Cyclophosphamide
2
trioctyl phosphine oxide
1
temsirolimus
1
sargramostim
1
pegfilgrastim
1
omburtamab I-131
1
montanide ISA 51
1
ixabepilone
1
ganitumab
1
entinostat
1
cixutumumab
1
amino-acid, glucose, and electrolyte solution
1
alvocidib
1
aldesleukin
1
Valproic Acid
1
Transplantation
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroectodermal Tumors, Primitive, Peripheral
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled